7:45 am Morning Networking Coffee & Registration

8:35 am Chairperson’s Opening Remarks

Navigating the Future Outlook of Successful mRNA-Based Vaccines and Therapeutics

8:45 am mRNA-1273 (Spikevax) – The Past, Present, & Future?

Synopsis

  • Adult vaccine development
  • Pediatric vaccine development
  • Variant vaccine development

9:15 am Pharma Leaders Fireside Discussion

  • Jacob Becraft Co-Founder & CEO, Strand Therapeutics
  • Kathy Fernando VP, Head of Worldwide Research, Development and Medical Operations; Head of mRNA Scientific Planning, Pfizer
  • Regis Gervier Global Head mRNA Center of Excellence , Sanofi
  • Hao Chen Global Head of Cell & Viral Drug Substance, GlaxoSmithKline

Synopsis

With the next wave of mRNA on the rise and with large pharma that were involved in prepandemic now having a validated platform on their hands to develop new therapeutics and vaccines, this leads to the inevitable question: What comes next? It is now important to realize the opportunities of such mRNA- based therapeutic applications, the
opportunities to develop global partnerships and collaboration as we hear from leading experts on the future of this technology

10:00 am Session Details To Be Confirmed

10:30 am Morning Structured Networking

1:00 pm Networking Lunch & Tech Slam

4:00 pm Afternoon Networking Break

4:30 pm Reserved for Applied DNA Sciences

Synopsis

  • Session Details To Be Confirmed

5:00 pm Diversity, Equality & Inclusion Round Table: Prioritizing Diversity, Equality & Inclusion in the mRNA Industry

  • Linda Marban CEO, Capricor Therapeutics
  • Hamideh Parhiz Research Assistant Professor of Medicine, Perelman School of Medicine, University of Pennsylvania
  • Tamar Grossman Global Head - RNA & Targeted Therapeutics , The Janssen Pharmaceutical Companies of Johnson & Johnson
  • Jane True VP - mRNA Commercial Development, Pfizer

Synopsis

  • What impacts are there on talent strategy in organizations today?
  • What is something actionable people can do today to make the scientific field more inclusive?
  • What developments and practices have organizations made or put in place that other leaders should consider adopting?

5:30 pm An Overview of the mRNA Landscape & Future Directions

Synopsis

  • A brief overview of the RNA drug and trial landscape
  • An in-depth analysis of the mRNA space and its development
  • A look into the future of mRNA and emerging trends

6:00 pm
Chair’s Closing Remarks & End of Conference Day One